Antulio Casiano Sosa, MD
Family Medicine · Carolina, PRNPI 1215934260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 31.5% of the total. Reporting peaked in 2019 at $507 and has fallen 51.1% since, to $248 in 2025. Among family medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $40.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$835
- Boehringer Ingelheim$639
- Bayer$275
- E.r. Squibb & Sons, L.L.C.$185
- Bayer Puerto Rico Inc.$173
- Biohaven Pharmaceutical Holding Company Ltd.$150
- plus $390 from 4 others
What the payments were for
- Food & beverage$2,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $835 |
| Boehringer Ingelheim | 25 | $639 |
| Bayer | 3 | $275 |
| E.r. Squibb & Sons, L.L.C. | 2 | $185 |
| Bayer Puerto Rico Inc. | 7 | $173 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $150 |
| GSK | 2 | $129 |
| Merck | 3 | $121 |
| Johnson & Johnson | 1 | $87 |
| PBG Puerto Rico LLC | 2 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$361
- Kerendia$250
- BREZTRI$242
- ANORO ELLIPTA$123
How this compares
$2,646 in reported general payments places this provider in the 95th percentile of 497 family medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 159 | $125,039 |
| XareltoRivaroxaban | 131 | $82,542 |
| JardianceEmpagliflozin | 95 | $80,222 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $50,067 |
| SynthroidLevothyroxine Sodium | 810 | $45,030 |
| EliquisApixaban | 52 | $29,914 |
| SynjardyEmpagliflozin/Metformin Hcl | 43 | $25,525 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 32 | $24,240 |
| TradjentaLinagliptin | 19 | $20,249 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $18,014 |
| Candesartan Cilexetil | 109 | $15,800 |
| Atorvastatin Calcium | 899 | $12,862 |
| JentaduetoLinagliptin/Metformin Hcl | 14 | $12,744 |
| LantusInsulin Glargine,hum.Rec.Anlog | 127 | $11,011 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Trijardy Xr, Tradjenta, Jentadueto | $639 | $162,980203 claims |
| AstraZenecaFarxiga | $835 | $125,039159 claims |
| Johnson & JohnsonXarelto | $87 | $82,542131 claims |
| MerckJanumet | $121 | $50,06738 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $129 | $26,69548 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 family medicine providers in Puerto Rico.
Other family medicine in Carolina
- Freddy Sallent AquinoCarolina$11K
- Maylynn Tossas MojicaCarolina$3K
- Alex Andujar AlejandroCarolina$3K
- Lizette Santiago ColonSan Juan$279K
- Ivan Melendez-RiveraPonce$183K
- Beigno GonzalezSan Juan$66K
- Francisco Murphy RiveraAdjuntas$34K
- Angela DuqueSan Juan$15K
- Carlos SariolSan Juan$12K
- Jose Mulero FernandezSan Juan$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.